Advances in the Treatment of Non –Small Cell Lung Cancer
Clinical development of immune checkpoint blockade has dramatically changed the treatment paradigm and prognosis for patients with non –small cell lung cancer. Immune checkpoint blockade with PD-1 and PD-L1 antibodies generates clinically significant, durable responses in patients with advanced non–small cell lung cancer. These agents are approved for first- and second-line treatment, either as single agents or in combination w ith chemotherapy and angiogenesis inhibitors. Although the toxicity profile of these treatments is favorable, a unique set of immune-mediated adverse events, such as pneumonitis, has been observed. Broader use of these agents is improving survival for patients with advanced lung cancer.
Source: Clinics in Chest Medicine - Category: Respiratory Medicine Authors: Shetal A. Patel, Jared Weiss Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Respiratory Medicine | Toxicology